By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for...

By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the...

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief...

By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany,...

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two...

By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or...